Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/105326
Título: | Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways | Autor: | Cano, Amanda Fonseca, Elena Ettcheto, Miren Sánchez-López, Elena de Rojas, Itziar Alonso-Lana, Silvia Morató, Xavier Souto, Eliana B. Toledo, Manuel Boada, Mercè Marquié, Marta Ruíz, Agustín |
Palavras-chave: | epilepsy; neurodegenerative diseases; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; multiple sclerosis | Data: | 18-Out-2021 | Editora: | MDPI | Projeto: | Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I) Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated into the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grant PI17/01474 Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated into the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grant PI19/00335 European Social Fund (ESF “Investing in your future”) Contract (CD19/00232) to SA-L Spanish Ministry of Economy and Competitiveness under the project SAF2017- 84283-R CIBERNED under project CB06/05/0024 UIDB/04469/2020 CIBERNED (Instituto de Salud Carlos III (ISCIII)), the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED GrantNº 115975, from EXIT project, EU Euronanomed3 Program JCT2017 Grant Nº AC17/00100, from PREADAPT project Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097, and from grants PI13/02434, PI16/01861 BA19/00020, and PI19/01301. Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de Hacer Europa”), by Fundación bancaria “La Caixa” and Grífols SA (GR@ACE project). |
Título da revista, periódico, livro ou evento: | Pharmaceuticals | Volume: | 14 | Número: | 10 | Resumo: | Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the main hypothesis about the molecular processes that trigger epileptic seizures and promote the neurotoxic effects that lead to cell death focuses on the exacerbation of the glutamate pathway and the massive influx of Ca2+ into neurons by different factors. However, other mechanisms have been proposed, and most of them have also been described in other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, or multiple sclerosis. Interestingly, and mainly because of these common molecular links and the lack of effective treatments for these diseases, some antiseizure drugs have been investigated to evaluate their therapeutic potential in these pathologies. Therefore, in this review, we thoroughly investigate the common molecular pathways between epilepsy and the major neurodegenerative diseases, examine the incidence of epilepsy in these populations, and explore the use of current and innovative antiseizure drugs in the treatment of refractory epilepsy and other neurodegenerative diseases. | URI: | https://hdl.handle.net/10316/105326 | ISSN: | 1424-8247 | DOI: | 10.3390/ph14101057 | Direitos: | openAccess |
Aparece nas coleções: | FFUC- Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
pharmaceuticals-14-01057-v2.pdf | 5.08 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
26
Visto em 6/mai/2024
Citações WEB OF SCIENCETM
25
Visto em 2/mai/2024
Visualizações de página
65
Visto em 7/mai/2024
Downloads
20
Visto em 7/mai/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons